Hypoxic Ischemic Encephalopathy

Number: 0812


Aetna considers total body cooling (TBC, also known as whole-body cooling) and/or selective head cooling (SHC) medically necessary for the treatment of neonates (28 days of age or younger) with moderate or severe hypoxic ischemic encephalopathy (HIE).

Aetna considers TBC and SHC experimental and investigational for other indications because their effectiveness for indications other than the one listed above has not been established.

Aetna considers the following adjunctive therapies experimental and investigational for the treatment of HIE because they have not been established as effective for the treatment of this condition (not an all-inclusive list):

  • Acupuncture
  • Adenosinergic agents
  • Allopurinol
  • Anti-tissue plasminogen activator
  • Apoptosis inhibitors (e.g., calyculin A, cyclosporin A, decylubiquinone, melatonin, and sodium phenylbutyrate)
  • Autologous cord blood cells
  • Cannabinoids
  • Docosahexaenoic acid
  • Erythropoietin
  • Growth factors (e.g., brain derived growth factor, insulin-like growth factor-1 (ILGF-1), and monosialo-gangliosides (GM1))
  • Inhaled carbon monoxide (CO) therapy
  • Magnesium
  • Monosialoganglioside
  • N-acetylcysteine
  • Nitric oxide synthase inhibitors (e.g., bromocriptine mesylate, camptothecin, chlorpromazine HCl, melatonin, and paroxetine HCl)
  • Platelet-activating factor antagonists
  • Photobiomodulation therapy
  • Stem cell therapy
  • Xenon (inhaled).

Aetna considers the following experimental and investigational as biomarkers for hypoxic ischemic encephalopathy:

  • Activin A
  • Creatine kinase brain isoenzyme (CK-BB) 
  • Glial fibrillary acidic protein (GFAP)
  • Interleukin-6 (IL-6)
  • MicroRNA (miRNA)
  • N-acetylaspartate (as a biomarker of outcome prediction for HIE)
  • Neuron-specific enolase (NSE)
  • Phosphorylated axonal neurofilament heavy chain (pNF-H)
  • S100 calcium-binding protein B (S-100β)
  • Soluble form of lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1)
  • Tau protein
  • Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1).

Notes: Therapeutic hypothermia (TH) should be administered to high-risk term neonates within 6 hrs of birth; TH may not be effective in asphyxiated newborns whose placentas show evidence of chorioamnionitis with fetal vasculitis and chorionic plate meconium.


Peri-natal asphyxia and resulting hypoxic ischemic encephalopathy (HIE) occur in 1 to 3 per 1000 births in the United States.  It is characterized by the need for resuscitation at birth, neurological depression, seizures as well as electroencephalographical abnormalities.  Hypoxic-ischemic encephalopathy is the major cause of encephalopathy in the neonatal period and represents a major cause of mortality and long-term morbidity in affected infants.  Until recently, management of a newborn with HIE has consisted mainly of supportive care to restore and maintain cerebral perfusion, provide adequate gas exchange and treat seizures with anti-convulsants.  Recent randomized controlled trials (RCTs) have shown that mild therapeutic hypothermia (TH) initiated within 6 hrs of birth reduces death as well as neurodevelopmental disabilities at 18 months of age in surviving infants.  Cooling can be accomplished through total body cooling (TBC, also known as whole-body cooling) or selective head cooling (SHC).  Meta-analysis of these trials suggested that for every 6 or 7 infants with moderate to severe HIE who are treated with mild hypothermia, there will be 1 fewer infant who dies or has significant neurodevelopmental disability.  In response to this evidence, major policy makers and guideline developers have recommended that cooling therapy be offered to infants with moderate to severe HIE (Selway 2010; Pfister and Soll, 2010).

In a multi-center RCT, Gluckman and colleagues (2005) examined if delayed head cooling can improve neurodevelopmental outcome in babies with neonatal encephalopathy.  A total of 234 term infants with moderate to severe neonatal encephalopathy and abnormal amplitude integrated electroencephalography (aEEG) were randomly assigned to either head cooling for 72 hrs, within 6 hrs of birth, with rectal temperature maintained at 34 to 35 degrees C (n = 116), or conventional care (n = 118).  Primary outcome was death or severe disability at 18 months.  Analysis was by intention-to-treat.  These investigators examined in 2 pre-defined subgroup analyses the effect of hypothermia in babies with the most severe aEEG changes before randomization -- i.e., severe loss of background amplitude, and seizures -- and those with less severe changes.  In 16 babies, follow-up data were not available.  Thus, in 218 infants (93 %), 73/110 (66 %) allocated conventional care and 59/108 (55 %) assigned head cooling died or had severe disability at 18 months (odds ratio 0.61; 95 % confidence interval [CI]: 0.34 to 1.09, p = 0.1).  After adjustment for the severity of aEEG changes with a logistic regression model, the odds ratio for hypothermia treatment was 0.57 (0.32 to 1.01, p = 0.05).  No difference was noted in the frequency of clinically important complications.  Pre-defined subgroup analysis suggested that head cooling had no effect in infants with the most severe aEEG changes (n = 46, 1.8; 0.49 to 6.4, p = 0.51), but was beneficial in infants with less severe aEEG changes (n = 172, 0.42; 0.22 to 0.80, p = 0.009).  These data suggested that although induced head cooling is not protective in a mixed population of infants with neonatal encephalopathy, it could safely improve survival without severe neurodevelopmental disability in infants with less severe aEEG changes.

Shankaran et al (2005) conducted a randomized trial of hypothermia in infants with a gestational age of at least 36 weeks who were admitted to the hospital at or before 6 hrs of age with either severe acidosis or peri-natal complications and resuscitation at birth and who had moderate or severe encephalopathy.  Infants were randomly assigned to usual care (control group) or whole-body cooling to an esophageal temperature of 33.5 degrees C for 72 hrs, followed by slow re-warming (hypothermia group).  Neurodevelopmental outcome was assessed at 18 to 22 months of age.  The primary outcome was a combined end point of death or moderate or severe disability.  Of 239 eligible infants, 102 were assigned to the hypothermia group and 106 to the control group.  Adverse events were similar in the 2 groups during the 72 hrs of cooling.  Primary outcome data were available for 205 infants.  Death or moderate or severe disability occurred in 45 of 102 infants (44 %) in the hypothermia group and 64 of 103 infants (62 %) in the control group (risk ratio, 0.72; 95 % CI: 0.54 to 0.95; p = 0.01).  Twenty-four infants (24 %) in the hypothermia group and 38 (37 %) in the control group died (risk ratio, 0.68; 95 % CI: 0.44 to 1.05; p = 0.08).  There was no increase in major disability among survivors; the rate of cerebral palsy was 15 of 77 (19 %) in the hypothermia group as compared with 19 of 64 (30 %) in the control group (risk ratio, 0.68; 95 % CI: 0.38 to 1.22; p = 0.20).  The authors concluded that whole-body hypothermia reduces the risk of death or disability in infants with moderate or severe HIE.
In the Total Body Hypothermia for Neonatal Encephalopathy (TOBY) trial, Azzopardi and colleagues (2009) performed a randomized study of infants who were less than 6 hrs of age and had a gestational age of at least 36 weeks and peri-natal asphyxial encephalopathy.  These researchers compared intensive care plus cooling of the body to 33.5 degrees C for 72 hrs and intensive care alone.  The primary outcome was death or severe disability at 18 months of age.  Pre-specified secondary outcomes included 12 neurological outcomes and 14 other adverse outcomes.  Of 325 infants enrolled, 163 underwent intensive care with cooling, and 162 underwent intensive care alone.  In the cooled group, 42 (25.8 %) infants died and 32 (19.6 %) survived but had severe neurodevelopmental disability, whereas in the non-cooled group, 44 (27.1 %) infants died and 42 (25.9 %) had severe disability (relative risk [RR] for either outcome, 0.86; 95 % CI: 0.68 to 1.07; p = 0.17).  Infants in the cooled group had an increased rate of survival without neurological abnormality (RR, 1.57; 95 % CI: 1.16 to 2.12; p = 0.003).  Among survivors, cooling resulted in reduced risks of cerebral palsy (RR, 0.67; 95 % CI: 0.47 to 0.96; p = 0.03) and improved scores on the Mental Developmental Index and Psychomotor Developmental Index of the Bayley Scales of Infant Development II (p = 0.03 for each) and the Gross Motor Function Classification System (p = 0.01).  Improvements in other neurological outcomes in the cooled group were not significant.  Adverse events were mostly minor and not associated with cooling.  The authors concluded that induction of moderate hypothermia for 72 hrs in infants who had peri-natal asphyxia did not significantly reduce the combined rate of death or severe disability but resulted in improved neurological outcomes in survivors.
Rutherford et al (2010) ascertained the effect of TH on neonatal cerebral injury.  These researchers assessed cerebral lesions on magnetic resonance imaging (MRI) scans of infants who participated in the Total TOBY trial.  In the TOBY trial, HIE was graded clinically according to the changes seen on amplitude integrated EEG, and infants were randomly assigned to intensive care with or without cooling.  The relation between allocation to hypothermia or normothermia and cerebral lesions was assessed by logistic regression with peri-natal factors as co-variates, and adjusted odds ratios (ORs) were calculated.  A total of 325 infants were recruited in the TOBY trial.  Images were available for analysis from 131 infants.  Therapeutic hypothermia was associated with a reduction in lesions in the basal ganglia or thalamus (OR 0.36, 95 % CI: 0.15 to 0.84; p = 0.02), white matter (0.30, 0.12 to 0.77; p = 0.01), and abnormal posterior limb of the internal capsule (0.38, 0.17 to 0.85; p = 0.02).  Compared with non-cooled infants, cooled infants had fewer scans that were predictive of later neuromotor abnormalities (0.41, 0.18 to 0.91; p = 0.03) and were more likely to have normal scans (2.81, 1.13 to 6.93; p = 0.03).  The accuracy of prediction by MRI of death or disability to 18 months of age was 0.84 (0.74 to 0.94) in the cooled group and 0.81 (0.71-0.91) in the non-cooled group.  The authors concluded that TH decreases brain tissue injury in infants with HIE.  The predictive value of MRI for subsequent neurological impairment is not affected by TH.
Lando et al (2010) studied the effects of induced hypothermia in infants born with HIE.  This retrospective study comprised data from medical records of newborn children born with HIE during a period of 32 months.  Relevant data for cooling were recorded.  Structured neurological examinations were carried out on survivors when they were 10 and/or 18 months old.  A total of 32 infants fulfilled the criteria for cooling, the incidence being 0.4/1000 births.  Twenty infants were cooled for 72 hrs.  Eleven infants had cooling discontinued before 72 hrs because of their grave prognosis.  One infant had cooling discontinued because of pulmonary hypertension.  Most infants were cooled before 6 hrs of age (median of 4 hrs).  The mortality rate was 41 %.  A total of 45 % were cooled without being placed in a ventilator.  The side effects were of no major concern.  Eight children had a neurological follow-up.  One child had developed cerebral palsy and 2 children suffered delayed development.  Total body cooling was carried out before 6 hrs of age in the vast majority of infants born with HIE.  Side effects were of less concern.  Respiratory support with a ventilator could be avoided in 45 % of the infants cooled for 72 hrs; the mortality rate was 41 %.
Simbruner et al (2010) noted that mild hypothermia after peri-natal HIE reduces neurological sequelae without significant adverse effects, but studies are needed to determine the most-efficacious methods.  In the neo.nEURO.network trial, term neonates with clinical and electrophysiological evidence of HIE were assigned randomly to either a control group, with a rectal temperature of 37°C (range of 36.5 to 37.5°C), or a hypothermia group, cooled and maintained at a rectal temperature of 33.5°C (range of 33 to 34°C) with a cooling blanket for 72 hrs, followed by slow re-warming.  All infants received morphine (0.1 mg/kg) every 4 hrs or an equivalent dose of fentanyl.  Neurodevelopmental outcomes were assessed at the age of 18 to 21 months.  The primary outcome was death or severe disability.  A total of 129 newborn infants were enrolled, and 111 infants were evaluated at 18 to 21 months (53 in the hypothermia group and 58 in the normothermia group).  The rates of death or severe disability were 51 % in the hypothermia group and 83 % in the normothermia group (p = 0.001; OR: 0.21 [95 % CI: 0.09 to 0.54]; number needed to treat (NNT): 4 [95 % CI: 3 to 9]).  Hypothermia also had a statistically significant protective effect in the group with severe HIE (n = 77; p = 0.005; OR: 0.17 [95 % CI: 0.05 to 0.57]).  Rates of adverse events during the intervention were similar in the 2 groups except for fewer clinical seizures in the hypothermia group.  The authors concluded that systemic hypothermia in the neo.nEURO.network trial showed a strong neuroprotective effect and was effective in the severe HIE group.
Sarkar et al (2009) compared the multi-organ dysfunction in infants receiving TH induced by either SHC or TBC.  In 59 asphyxiated newborns who received TH by either SHC (n = 31) or TBC (n = 28), the severity of pulmonary, hepatic and renal dysfunction and coagulopathy and electrolyte disturbances were assessed before the start of cooling (baseline), and at specific time intervals (24, 48 and 72 hrs) throughout cooling.  Enrollment criteria, clinical monitoring and treatment during cooling, whether SHC or TBC, were similar, as reported earlier.  The presence of clinical respiratory distress, along with the need for ventilatory support for varying duration during cooling, was similar in both the TBC and SHC groups (100 % versus 94 %, p = 0.49, OR 1.9, 95 % CI: 1.5 to 2.5).  The use of fresh frozen plasma and platelet transfusion to treat coagulopathy and thrombocytopenia was similar (TBC 48 % versus SHC 58 %, p = 0.59, OR 0.7, 95 % CI: 0.2 to 1.9, and TBC 41 % versus SHC 32 %, p = 0.58, OR 1.4, 95 % CI: 0.5 to 4.2, respectively), and equivalent numbers of infants from both groups were treated with vasopressors for greater than 24 hrs (TBC 59 % versus SHC 55 %, p = 0.79, OR 1.2, 95 % CI: 0.4 to 3.4).  The incidence of oliguria (urine output less than 0.5 ml/kg/hr for greater than 24 hrs after birth) and rising serum creatinine (with maximum serum creatinine greater than 0.9 mg/dl) was also similar (TBC 18 % versus SHC 39 %, p = 0.15, OR 0.4, 95 % CI: 0.1 to 1.3, and TBC 48 % versus SHC 58 %, p = 0.59, OR 0.7, 95 % CI: 0.2 to 1.9, respectively).  Laboratory parameters to assess the differential effect of TBC versus SHC on multi-organ dysfunction during 72 hrs of cooling, which include serum transaminases (serum aspartate aminotransferase and alanine aminotransferase), prothrombin time, partial thromboplastin time, international normalized ratio (INR), platelet counts, serum creatinine, serum sodium, serum potassium and serum calcium, were similar between the groups at the initiation of cooling and did not differ with the method of cooling.  The authors concluded that multi-organ system dysfunction in asphyxiated newborns during cooling remains similar for both cooling methods.  Concerns regarding a differential effect of TBC versus SHC on multi-organ dysfunction, other than of the brain, should not be a consideration in selecting a method to produce therapeutic hypothermia.
In a multi-center RCT, Zhou et al (2010) examined the safety and the effectiveness of SHC with mild systemic hypothermia in HIE.  Infants with HIE were randomly assigned to the SHC  or control group.  Selective head cooling was initiated within 6 hrs after birth to a nasopharyngeal temperature of 34 +/- 0.2 degrees C and rectal temperature of 34.5 to 35.0 degrees C for 72 hrs.  Rectal temperature was maintained at 36.0 to 37.5 degrees C in the control group.  Neurodevelopmental outcome was assessed at 18 months of age.  The primary outcome was a combined end point of death and severe disability.  A total of 194 infants were available for analysis (100 and 94 infants in the SHC and control group, respectively).  For the SHC and control groups, respectively, the combined outcome of death and severe disability was 31 % and 49 % (OR: 0.47; 95 % CI: 0.26 to 0.84; p = 0.01), the mortality rate was 20 % and 29 % (OR:0.62; 95 % CI: 0.32 to 1.20; p = 0.16), and the severe disability rate was 14 % (11/80) and 28 % (19/67) (OR: 0.40; 95 % CI: 0.17 to 0.92; p = 0.01).  The authors concluded that SHC combined with mild systemic hypothermia for 72 hrs may significantly decrease the combined outcome of severe disability and death, as well as severe disability.

Schulzke et al (2007) reviewed RCTs assessing TH as a treatment for term neonates with HIE.  The Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CINAHL databases, reference lists of identified studies, and proceedings of the Pediatric Academic Societies were searched in July 2006.  Randomized trials assessing the effect of TH by either selective head cooling or whole-body cooling in term neonates were eligible for inclusion in the meta-analysis.  The primary outcome was death or neurodevelopmental disability at greater than or equal to 18 months.  A total of 5 trials involving 552 neonates were included in the analysis.  Cooling techniques and the definition and severity of neurodevelopmental disability differed between studies.  Overall, there is evidence of a significant effect of TH on the primary composite outcome of death or disability (RR: 0.78, 95 % CI: 0.66 to 0.92, NNT: 8, 95 % CI: 5 to 20) as well as on the single outcomes of mortality (RR: 0.75, 95 % CI: 0.59 to 0.96) and neurodevelopmental disability at 18 to 22 months (RR: 0.72, 95 % CI: 0.53 to 0.98).  Adverse effects include benign sinus bradycardia (RR: 7.42, 95 % CI: 2.52 to 21.87) and thrombocytopenia (RR: 1.47, 95 % CI: 1.07 to 2.03, NNH: 8) without deleterious consequences.  The authors concluded that in general, TH seems to have a beneficial effect on the outcome of term neonates with moderate to severe HIE.  Despite the methodological differences between trials, wide confidence intervals, and the lack of follow-up data beyond the second year of life, the consistency of the results is encouraging.
In a Cochrane review, Jacobs et al (2007) examined the effect of TH in HIE newborn infants on mortality, long-term neurodevelopmental disability and clinically important side effects.  Randomized controlled trials comparing the use of TH with standard care in encephalopathic newborn infants with evidence of peri-partum asphyxia and without recognizable major congenital anomalies were included.  The primary outcome measure was death or long-term major neurodevelopmental disability.  Other outcomes included adverse effects of cooling and "early" indicators of neurodevelopmental outcome.  Three review authors independently selected, assessed the quality of and extracted data from the included studies.  Authors were contacted for further information.  Meta-analyses were performed using RR and risk difference (RD) for dichotomous data, and weighted mean difference for continuous data with 95 % CI.  A total of 8 RCTs were included in this review, comprising 638 term infants with moderate/severe encephalopathy and evidence of intra-partum asphyxia.  Therapeutic hypothermia resulted in a statistically significant and clinically important reduction in the combined outcome of mortality or major neurodevelopmental disability to 18 months of age [typical RR 0.76 (95 % CI: 0.65 to 0.89), typical RD -0.15 (95 % CI: -0.24 to -0.07), NNT 7 (95 % CI: 4 to 14)].  Cooling also resulted in statistically significant reductions in mortality [typical RR 0.74 (95 % CI: 0.58 to 0.94), typical RD -0.09 (95 % CI: -0.16 to -0.02), NNT 11 (95 % CI: 6 to 50)] and in neurodevelopmental disability in survivors [typical RR 0.68 (95 % CI: 0.5 to 0.92), typical RD -0.13 (95 % CI: -0.23 to -0.03), NNT 8 (95 % CI: 4 to 33)].  Some adverse effects of hypothermia included an increase in the need for inotrope support of borderline significance and a significant increase in thrombocytopaenia.  The authors concludedthat there is evidence from the 8 RCTs included in this systematic review (n = 638) that TH is beneficial to term newborns with HIE.  Cooling reduces mortality without increasing major disability in survivors.  The benefits of cooling on survival and neurodevelopment outweigh the short-term adverse effects.  However, this review comprised an analysis based on less than 50 % of all infants currently known to be randomized into eligible trials of cooling.  Incorporation of data from ongoing and completed randomised trials (n = 829) will be important to clarify the effectiveness of TH and to provide more information on the safety of TH, but could also alter these conclusions.
In a meta-analysis, Edwards et al (2010) examined if moderate hypothermia after HIE in neonates improves survival and neurological outcome at 18 months of age.  Studies were identified from the Cochrane central register of controlled trials, the Oxford database of peri-natal trials, PubMed, previous reviews, and abstracts.  Reports that compared TBC or SHC with normal care in neonates with HIE and that included data on death or disability and on specific neurological outcomes of interest to patients and clinicians were selected.  These researchers found 3 trials, encompassing 767 infants, that included information on death and major neurodevelopmental disability after at least 18 months' follow-up.  They also identified 7 other trials with mortality information but no appropriate neurodevelopmental data.  Therapeutic hypothermia significantly reduced the combined rate of death and severe disability in the 3 trials with 18 month outcomes (RR 0.81, 95 % CI: 0.71 to 0.93, p = 0.002; RD -0.11, 95 % CI: -0.18 to -0.04), with a NNT of 9 (95 % CI: 5 to 25).  Hypothermia increased survival with normal neurological function (RR 1.53, 95 % CI: 1.22 to 1.93, p < 0.001; RD 0.12, 95 % CI: 0.06 to 0.18), with a NNT of 8 (95 % CI: 5 to 17), and in survivors reduced the rates of severe disability (p = 0.006), cerebral palsy (p = 0.004), and mental and the psychomotor developmental index of less than 70 (p = 0.01 and p = 0.02, respectively).  No significant interaction between severity of encephalopathy and treatment effect was detected.  Mortality was significantly reduced when these investigators assessed all 10 trials (1320 infants; RR 0.78, 95 % CI: 0.66 to 0.93, p = 0.005; RD -0.07, 95 % CI: -0.12 to -0.02), with a NNT of 14 (95 % CI: 8 to 47).  The authors concluded that in infants with HIE, moderate hypothermia is associated with a consistent reduction in death and neurological impairment at 18 months.
In a systematic review and meta-analysis, Shah (2010) analyzed 13 clinical trials published to date on TH for the treatment of HIE.  Therapeutic hypothermia was associated with a highly reproducible reduction in the risk of the combined outcome of mortality or moderate-to-severe neurodevelopmental disability in childhood.  This improvement was internally consistent, as shown by significant reductions in the individual risk for death, moderate-to-severe neurodevelopmental disability, severe cerebral palsy, cognitive delay, and psychomotor delay.  Patients in the TH group had higher incidences of arrhythmia and thrombocytopenia; however, these were not clinically important.  This analysis supports the use of TH in reducing the risk of the mortality or moderate-to-severe neurodevelopmental disability in infants with moderate HIE.
Perlman (2006) stated that recent evidence suggested a potential role for modest hypothermia administered to high-risk term infants within 6 hrs of birth.  Either SHC or TBC reduces the incidence of death and/or moderate to severe disability at 18-month follow-up.  Additional strategies -- including the use of oxygen free radical inhibitors and scavengers, excitatory amino acid antagonists, and growth factors; prevention of nitric oxide formation; and blockage of apoptotic pathways -- have been evaluated experimentally but have not been replicated in a systematic manner in the human neonate.  Other avenues of potential neuroprotection that have been studied in immature animals include adenosinergic agents, erythropoietin, insulin-like growth factor-1, monosialoganglioside GM1, and platelet-activating factor antagonists.

In a randomized, prospective study, Zhu and colleagues (2009) assessed the safety and effectiveness of erythropoietin in neonatal HIE.  A total of 167 term infants with moderate/severe HIE were assigned randomly to receive either erythropoietin (n = 83) or conventional treatment (n = 84).  Recombinant human erythropoietin, at either 300 U/kg body weight (n = 52) or 500 U/kg (n = 31), was administered every other day for 2 weeks, starting less than 48 hrs after birth.  The primary outcome was death or disability.  Neurodevelopmental outcomes were assessed at 18 months of age.  Complete outcome data were available for 153 infants; 9 patients dropped out during treatment, and 5 patients were lost to follow-up monitoring.  Death or moderate/severe disability occurred for 35 (43.8 %) of 80 infants in the control group and 18 (24.6 %) of 73 infants in the erythropoietin group (p = 0.017) at 18 months.  The primary outcomes were not different between the 2 erythropoietin doses.  Subgroup analyses indicated that erythropoietin improved long-term outcomes only for infants with moderate HIE (p = 0.001) and not those with severe HIE (p = 0.227).  No negative hematopoietic side effects were observed.  The authors concluded that repeated, low-dose, recombinant human erythropoietin treatment reduced the risk of disability for infants with moderate HIE, without apparent side effects.  The findings of this preliminary study need to be validated by a larger clinical trial.
Cilio and Ferriero (2010) noted that with the advent of hypothermia as therapy for term HIE, there is hope for repair and protection of the brain after a profound neonatal insult.  However, it is clear from the published clinical trials and animal studies that hypothermia alone will not provide complete protection or stimulate the repair that is necessary for normal neurodevelopmental outcome.  This review critically discusses drugs used to treat seizures after hypoxia-ischemia in the neonate with attention to evidence of possible synergies for therapy.  In addition, other agents such as cannabinoids, erythropoietin, melatonin, N-acetylcysteine, and xenon were discussed as future potential therapeutic agents that might augment protection from hypothermia.

Wintermark and colleagues (2010) described placental findings in asphyxiated term newborns meeting TH criteria and examined if histopathological correlation exists between these placental lesions and the severity of later brain injury.  These investigators conducted a prospective cohort study of the placentas of asphyxiated newborns, in whom later brain injury was defined by magnetic resonance imaging.  A total of 23 newborns were enrolled.  Eighty-seven percent of their placentas had an abnormality on the fetal side of the placenta, including umbilical cord lesions (39 %), chorioamnionitis (35 %) with fetal vasculitis (22 %), chorionic plate meconium (30 %), and fetal thrombotic vasculopathy (26 %).  A total of 48 % displayed placental growth restriction.  Chorioamnionitis with fetal vasculitis and chorionic plate meconium were significantly associated with brain injury (p = 0.03).  Placental growth restriction appears to significantly offer protection against the development of these injuries (p = 0.03).  The authors concluded that TH may not be effective in asphyxiated newborns whose placentas show evidence of chorioamnionitis with fetal vasculitis and chorionic plate meconium.

Shankaran and colleagues (2011) examined the predictive validity of the amplitude-integrated electroencephalogram (aEEG) and stage of encephalopathy among infants with HIE eligible for therapeutic whole-body hypothermia.  Neonates were eligible for this prospective study if moderate or severe HIE occurred at less than 6 hours and an aEEG was obtained at less than 9 hours of age.  The primary outcome was death or moderate/severe disability at 18 months.  There were 108 infants (71 with moderate HIE and 37 with severe HIE) enrolled in the study.  Amplitude-integrated EEG findings were categorized as normal, with continuous normal voltage (n = 12) or discontinuous normal voltage (n = 12), or abnormal, with burst suppression (n = 22), continuous low voltage (n = 26), or flat tracing (n = 36).  At 18 months, 53 infants (49 %) experienced death or disability.  Severe HIE and an abnormal aEEG were related to the primary outcome with uni-variate analysis, whereas severe HIE alone was predictive of outcome with multi-variate analysis.  Addition of aEEG pattern to HIE stage did not add to the predictive value of the model; the area under the curve changed from 0.72 to 0.75 (p = 0.19).  The authors concluded that the aEEG background pattern did not significantly enhance the value of the stage of encephalopathy at study entry in predicting death and disability among infants with HIE.

Shankaran and colleagues (2012) previously reported early results of a randomized trial of whole-body hypothermia for neonatal HIE showing a significant reduction in the rate of death or moderate or severe disability at 18 to 22 months of age.  These investigators reported long-term outcomes in this study.  In the original trial, the authors assigned infants with moderate or severe encephalopathy to usual care (the control group) or whole-body cooling to an esophageal temperature of 33.5°C for 72 hours, followed by slow re-warming (the hypothermia group).  They evaluated cognitive, attention and executive, and visuo-spatial function; neurologic outcomes; and physical and psychosocial health among participants at 6 to 7 years of age.  The primary outcome of the present analyses was death or an IQ score below 70.  Of the 208 trial participants, primary outcome data were available for 190.  Of the 97 children in the hypothermia group and the 93 children in the control group, death or an IQ score below 70 occurred in 46 (47 %) and 58 (62 %), respectively (p = 0.06); death occurred in 27 (28 %) and 41 (44 %) (p = 0.04); and death or severe disability occurred in 38 (41 %) and 53 (60 %) (p = 0.03).  Other outcome data were available for the 122 surviving children, 70 in the hypothermia group and 52 in the control group.  Moderate or severe disability occurred in 24 of 69 children (35 %) and 19 of 50 children (38 %), respectively (p = 0.87).  Attention-executive dysfunction occurred in 4 % and 13 %, respectively, of children receiving hypothermia and those receiving usual care (p = 0.19), and visuo-spatial dysfunction occurred in 4 % and 3 % (p = 0.80).  The authors concluded that the rate of the combined end point of death or an IQ score of less than 70 at 6 to 7 years of age was lower among children undergoing whole-body hypothermia than among those undergoing usual care, but the differences were not significant.  However, hypothermia resulted in lower death rates and did not increase the rates of a low IQ score or severe disability among survivors.  These data extend the authors' previous support for the use of hypothermia in term as well as near-term infants with HIE.

In a Cochrane review, Chaudhari and McGuire (2012) examined the effect of allopurinol, a xanthine-oxidase inhibitor, on mortality and morbidity in newborn infants with HIE.  These investigators used the standard search strategy of the Cochrane Neonatal Group.  They searched the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, 2012, Issue 1), MEDLINE (1966 to March 2012), EMBASE (1980 to March 2012), CINAHL (1982 to March 2012), conference proceedings, and previous reviews.  Randomized or quasi-RCTs that compared allopurinol administration versus placebo or no drug in newborn infants with HIE wer selected for review.  These researchers extracted data using the standard methods of the Cochrane Neonatal Review Group with separate evaluation of trial quality and data extraction by 2 review authors.  They included 3 trials in which a total of 114 infants participated.  In 1 trial, participants were exclusively infants with severe encephalopathy.  The other trials also included infants with mild and moderately severe encephalopathy.  These studies were generally of good methodological quality, but were too small to exclude clinically important effects of allopurinol on mortality and morbidity.  Meta-analysis did not reveal a statistically significant difference in the risk of death (typical risk ratio 0.88; 95 % CI: 0.56 to 1.38; risk difference -0.04; 95 % CI: -0.18 to 0.10) or a composite of death or severe neurodevelopmental disability (typical risk ratio 0.78; 95 % CI: 0.56 to 1.08; risk difference -0.14; 95 % CI: -0.31 to 0.04).  The authors concluded that the available data are insufficient to determine whether allopurinol has clinically important benefits for newborn infants with HIE.  They stated that much larger trials are needed.  Such trials could assess allopurinol as an adjunct to therapeutic hypothermia in infants with moderate and severe encephalopathy and should be designed to exclude important effects on mortality and adverse long-term neurodevelopmental outcomes.

In a Cochrane review, Wong et al (2013) examined the safety and effectiveness of acupuncture on mortality and morbidity in neonates with HIE.  These investigators searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), Cochrane Neonatal Specialized Register, MEDLINE, AMED, EMBASE, PubMed, CINAHL, PsycINFO, WHO International Clinical Trials Registry Platform, and various Chinese medical databases in November 2012.  They included RCTs or quasi-RCTs comparing needle acupuncture to a control group that used no treatment, placebo or sham treatment in neonates (less than 28 days old) with HIE.  Co-interventions were allowed as long as both the intervention and the control group received the same co-interventions.  They excluded trials that evaluated therapy that did not involve penetration of the skin with a needle or trials that compared different forms of acupuncture only.  Two review authors independently reviewed trials for inclusion.  If trials were identified, the review authors planned to assess trial quality and extract data independently.  These researchers used the risk ratio (RR), risk difference (RD), and number needed to benefit (NNTB) or harm (NNTH) with 95 % CI for dichotomous outcomes, and mean difference (MD) with 95 % CI for continuous outcomes.  No trial satisfied the pre-defined inclusion criteria.  Existing trials only evaluated acupuncture in older infants who survived HIE.  There are currently no RCTs evaluating the effectiveness of acupuncture for treatment of HIE in neonates.  The safety of acupuncture for HIE in neonates is unknown.  The authors concluded that the rationale for acupuncture in neonates with HIE is unclear and the evidence from RCT is lacking.  Therefore, the authors do not recommend acupuncture for the treatment of HIE in neonates; they stated that high quality RCTs on acupuncture for HIE in neonates are needed.

Tagin and colleagues (2013) systematically reviewed the safety and effectiveness of post-natal magnesium therapy in newborns with HIE.  MEDLINE, EMBASE, CINAHL and CCRCT were searched for studies of magnesium for HIE.  Randomized controlled trials that compared magnesium to control in newborns with HIE were selected.  The primary outcome was a composite outcome of death or moderate-to-severe neurodevelopmental disability at 18 months.  When appropriate, meta-analyses were conducted using random effects model and risk ratios (RRs) and 95 % CIs were calculated.  A total of 5 studies with sufficient quality were included.  There was no difference in the primary outcome between the magnesium and the control groups (RR 0.81, 95 % CI: 0.36 to 1.84).  There was significant reduction in the unfavorable short-term composite outcome (RR 0.48, 95 % CI: 0.30 to 0.77) but no difference in mortality (RR 1.39, 95 % CI: 0.85 to 2.27), seizures (RR 0.84, 95 % CI: 0.59 to 1.19) or hypotension (RR 1.28, 95 % CI: 0.69 to 2.38) between the magnesium and the control groups.  The authors concluded that the improvement in short-term outcomes without significant increase in side effects indicated the need for further trials to determine if there are long-term benefits of magnesium and to confirm its safety.  They noted that mortality was statistically insignificant between the magnesium and the control groups.  However, the trend toward increase in mortality in the magnesium group is a major clinical concern and should be monitored closely in future trials.

Cotton and associates (2014) evaluated the feasibility and safety of providing autologous umbilical cord blood (UCB) cells to neonates with HIE.  These investigators enrolled infants in the intensive care nursery who were cooled for HIE and had available UCB in an open-label study of non-cyropreserved autologous volume- and red blood cell-reduced UCB cells (up to 4 doses adjusted for volume and red blood cell content, 1-5 × 10(7) cells/dose).  They recorded UCB collection and cell infusion characteristics, and pre- and post-infusion vital signs.  As exploratory analyses, these researchers compared cell recipients' hospital outcomes (mortality, oral feeds at discharge) and 1-year survival with Bayley Scales of Infant and Toddler Development, 3rd edition scores greater than or equal to 85 in 3 domains (cognitive, language, and motor development) with cooled infants who did not have available cells.  A total of 23 infants were cooled and received cells.  Median collection and infusion volumes were 36 and 4.3 ml, respectively.  Vital signs including oxygen saturation were similar before and after infusions in the first 48 post-natal hours.  Cell recipients and concurrent cooled infants had similar hospital outcomes; 13 of 18 (74 %) cell recipients and 19 of 46 (41 %) concurrent cooled infants with known 1-year outcomes survived with scores greater than 85.  The authors concluded that collection, preparation, and infusion of fresh autologous UCB cells for use in infants with HIE is feasible.  Moreover, they stated that a randomized, double-blind, study is needed.

Gonzales-Portillo et al (2014) noted that treatments for neonatal HIE have been limited.  These researchers offered translational research guidance on stem cell therapy for neonatal HIE by examining clinically relevant animal models, practical stem cell sources, safety and effectiveness of end-point assays, as well as a general understanding of modes of action of this cellular therapy.  They discussed the clinical manifestations of HIE, high-lighting its overlapping pathologies with stroke and providing insights on the potential of cell therapy currently investigated in stroke, for HIE.  These investigators drew guidance from recommendations outlined in stem cell therapeutics as an emerging paradigm for stroke or STEPS, which have been recently modified to Baby STEPS to cater for the "neonatal" symptoms of HIE.  These guidelines recognized that neonatal HIE exhibit distinct disease symptoms from adult stroke in need of an innovative translational approach that facilitates the entry of cell therapy in the clinic.  The authors provided new information about recent clinical trials and insights into combination therapy with the vision that stem cell therapy may benefit from available treatments, such as hypothermia, already being tested in children diagnosed with HIE.

Yang and colleagues (2015) noted that in recent years, acupuncture has increasingly being integrated into pediatric health care. It was used on approximately 150,000 children (0.2 %). These researchers updated the evidence for the safety and effectiveness of acupuncture for children and evaluate the methodological qualities of these studies to improve future research in this area. They included 24 systematic reviews, comprising 142 RCTs with 12,787 participants. Only 25 % (6/24) reviews were considered to be high quality (10.00 ± 0.63). High-quality systematic reviews and Cochrane systematic reviews tend to yield neutral or negative results (p = 0.052, 0.009, respectively). The effectiveness of acupuncture for 5 diseases (cerebral palsy, nocturnal enuresis, tic disorders, amblyopia, and pain reduction) is promising. It was unclear for HIE, attention deficit hyperactivity disorder, mumps, autism spectrum disorder, asthma, nausea/vomiting, and myopia. Acupuncture is not effective for epilepsy. Only 6 reviews reported adverse events (AEs) and no fatal side effects were reported. The authors concluded that the effectiveness of acupuncture for some diseases is promising and there have been no fatal side effects reported. They stated that further high-quality studies are needed, with 5 diseases in particular as research priorities.

Atici and colleagues (2015) examined which method was superior by applying SHC or TBC therapy in newborns diagnosed with moderate or severe HIE. Newborns above the 35th gestational age diagnosed with moderate or severe HIE were included in the study and SHC or TBC therapy was performed randomly. The newborns who were treated by both methods were compared in terms of AEs in the early stage and in terms of short-term results. A total of 53 babies diagnosed with HIE were studied: SHC was applied to 17 babies and TBC was applied to 12 babies. There was no significant difference in terms of AEs related to cooling therapy between the 2 groups. When the short-term results were examined, it was found that the hospitalization time was 34 (7 to 65) days in the SHC group and 18 (7 to 57) days in the TBC group and there was no significant difference between the 2 groups (p = 0.097). Four patients in the SHC and 2 patients in the TBC group were discharged with tracheostomy because of the need for prolonged mechanical ventilation and there was no difference between the groups in terms of discharge with tracheostomy (p = 0.528). Five patients in the SHC group and 3 patients in the TBC group were discharged with a gastrostomy tube because they could not be fed orally and there was no difference between the groups in terms of discharge with a gastrostomy tube (p = 0.586). One patient who was applied SHC and 1 patient who was applied TBC died during hospitalization and there was no difference between the groups in terms of mortality (p = 0.665). The authors concluded that there was no difference between the methods of SHC and TBC in terms of adverse effects and short-term results.

Wu and colleagues (2015) stated that perinatal HIE occurs in 1 to 3 per 1000 term births. Hypoxic ischemic encephalopathy is not preventable in most cases, and therapies are limited. Hypothermia improves outcomes and is the current standard of care. Yet, clinical trials suggested that 44 to 53 % of infants who receive hypothermia will die or suffer moderate-to-severe neurological disability. These investigators reviewed the pre-clinical and clinical evidence for erythropoietin (EPO) as a potential novel neuro-protective agent for the treatment of HIE. Erythropoietin is a novel neuro-protective agent, with remarkable neuro-protective and neuro-regenerative effects in animals. Rodent and primate models of neonatal brain injury support the safety and effectiveness of multiple EPO doses for improving histological and functional outcomes after hypoxia-ischemia. Small clinical trials of EPO in neonates with HIE have also provided evidence supporting safety and preliminary effectiveness in humans. There is currently insufficient evidence to support the use of high-dose EPO in newborns with HIE. However, several on-going trials will provide much needed data regarding the safety and effectiveness of this potential new therapy when given in conjunction with hypothermia for HIE. Novel neuro-protective therapies are needed to further reduce the rate and severity of neurodevelopmental disabilities resulting from HIE. The authors concluded that high-dose EPO is a promising therapy that can be administered in conjunction with hypothermia. However, they stated that additional data are needed to determine the safety and effectiveness of this adjuvant therapy for HIE.


Celik and colleagues (2015) noted that TH has become standard care in newborns with moderate to severe HIE, and the 2 most commonly used methods are SHC and whole body cooling (WBC). In a pilot study, these investigators examined if the effects of the 2 methods on some neural and inflammatory biomarkers differ.  This pilot study included newborns delivered after greater than 36 weeks of gestation; SHC or WBC was administered randomly to newborns with moderate-to-severe HIE that were prescribed TH.  The serum interleukin (IL)-1β, IL-6, neuron-specific enolase (NSE), brain-specific creatine kinase (CK-BB), tumor necrosis factor-alpha (TNF-α), and protein S100 levels, the urine S100B level, and the urine lactate/creatinine (L/C) ratio were evaluated 6 and 72 hours after birth.  The Bayley Scales of Infant and Toddler Development-III was administered at month 12 for assessment of neurodevelopmental findings.  The SHC group included 14 newborns, the WBC group included 10, the mild HIE group included 7, and the control group included 9.  All the biomarker levels in the SHC and WBC groups at 6 and 72 hours were similar, and all the changes in the biomarker levels between 6 and 72 hours were similar in both groups.  The serum IL-6 and protein S100 levels at 6 hours in the SHC and WBC groups were significantly higher than in the control group.  The urine L/C ratio at 6 hours in the SHC and WBC groups was significantly higher than in the mild HIE and control groups.  The IL-6 level and L/C ratio at 6 and 72 hours in the patients who had died or had disability at month 12 were significantly higher than in the patients without disability at month 12.  The authors concluded that the effects of SHC and WBC on the biomarkers evaluated did not differ.  They stated that the urine L/C ratio might be useful for differentiating newborns with moderate and severe HIE from those with mild HIE.  Furthermore, the serum IL-6 level and the L/C ratio might be useful for predicting disability and mortality in newborns with HIE.

Lv and associates (2015) stated that the use of biomarkers to monitor brain injury and evaluate neuroprotective effects might allow the early intervention and treatment of neonatal HIE to reduce mortality rates.  These investigators reviewed the mechanism of neonatal HIE in relation to numerous brain-related biomarkers including activin A, creatine kinase brain isoenzyme (CK-BB)neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), lactate dehydrogenase (LDH), microRNA (miRNA), S100 calcium-binding protein B (S-100β), tau protein, and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1).  In early diagnosis of neonatal HIE, S-100β and activin A appeared to be better biomarkers.  Biomarkers with the greatest potential to predict long-term neurologic handicap of neonates with HIE are GFAP and UCH-L1 and when combined with other markers or brain imaging can increase the detection rate of HIE.  Tau protein is a unique biological component of nervous tissues, and might have value for neonatal HIE diagnosis.  Combination of more than 2 biological markers should be a future research direction.

Zaigham and colleagues (2016) compared UCH-L1 and GFAP concentrations in umbilical cord blood of neonates who develop Sarnat stage II to III HIE to healthy controls, and correlated the concentrations to the severity of neurology and long-time outcomes.  Cord sera of 15 neonates with HIE II to III and 31 matched controls were analyzed for UCH-L1 and GFAP.  Comparisons were performed for cord artery pH, amplitude-integrated electroencephalography (aEEG), stage of HIE, and death or sequelae up to an age of 6 years.  Parametric and non-parametric statistics were used with a 2-sided p < 0.05 considered significant.  Among controls no associations between biomarker concentrations and gestational age, birth-weight, length of storage of cord sera and degree of hemolysis were found.  No significant differences in biomarker concentrations were found between HIE neonates and controls, and no differences were found with regard to HIE stage, cord acidemia, severity of aEEG changes, or persistent sequelae or death.  The authors concluded that no differences in cord blood UCH-L1 and GFAP concentrations were found between HIE neonates and controls, and no associations were found between the biomarker concentrations and the severity of disease, or whether the condition developed into a permanent or fatal injury.

Martinello, et al. (2017) noted that various biomarkers of brain injury in blood, urine and CSF have been proposed, including S100 calcium-binding protein B (S100B), glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), creatine kinase brain band, neuron-specific enolase (NSE), malondialdehyde and proinflammatory cytokines. The authors stated that "[t][hese brain-specific proteins may be useful immediate biomarkers of cerebral injury severity but still need to be independently validated in large cohorts before they are ready for clinical implementation in practice."

Furthermore, UpToDate reviews on “Hypoxic-ischemic brain injury: Evaluation and prognosis” (Weinhouse and Young, 2017) and “Clinical features, diagnosis, and treatment of neonatal encephalopathy” (Wu, 2017) do not mention the use of biomarkers.

Patil and colleagues (2018) stated that evaluation of newborns for HIE includes laboratory and clinical parameters, as well as amplitude integrated electroencephalogram (aEEG).  Based on qualifying criteria, SHC is initiated for infants with evidence of moderate-to-severe HIE.  However, some newborns may not qualify for hypothermia therapy based on normal aEEG.  These researchers compared levels of serum GFAP, UCH-L1 protein and phosphorylated axonal neurofilament heavy chain (pNF-H), in newborns who met initial screening criteria for HIE but did not qualify for AHC, to the levels in healthy newborns.  Newborns greater than or equal to 36 weeks of gestational age at risk for HIE, who were evaluated but did not qualify for SHC from July 2013 through June 2014 at NYU Langone Medical Center and Bellevue Hospital center were enrolled in this study.  A control group included healthy newborns from the newborn nursery (NBN).  Serum samples were collected between 24 and 48 hours of life from both groups.  There was no significant difference in the serum levels of GFAP, UCH-L1 protein and pNF-H between the 2 groups of infants.  The authors concluded that newborns at risk for HIE who met the initial criteria for SHC but who were excluded based on normal aEEG did not show significant elevation of biomarkers of brain injury compared to healthy newborns.

Anti-Epileptic Drugs for Hypoxic Ischemic Encephalopathy-Associated Seizures

In an open-label, phase I/II clinical trial, Pressler et al (2015) examined dose and feasibility of intravenous bumetanide as an add-on to phenobarbital for treatment of neonatal seizures associated with HIE. These researchers recruited full-term infants younger than 48 hours who had HIE and electrographic seizures not responding to a loading-dose of phenobarbital from 8 neonatal intensive care units (ICUs) across Europe. Newborn babies were allocated to receive an additional dose of phenobarbital and 1 of 4 bumetanide dose levels by use of a bi-variate Bayesian sequential dose-escalation design to assess safety and effectiveness. They assessed AEs, pharmacokinetics, and seizure burden during 48 hours continuous EEG monitoring. The primary effectiveness end-point was a reduction in electrographic seizure burden of more than 80 % without the need for rescue anti-epileptic drugs in more than 50 % of infants. Between September 1, 2011 and September 28, 2013, these investigators screened 30 infants who had electrographic seizures due to HIE; 14 of these infants (10 boys) were included in the study (dose allocation: 0.05 mg/kg, n = 4; 0.1 mg/kg, n = 3; 0.2 mg/kg, n = 6; 0.3 mg/kg, n = 1). All babies received at least 1 dose of bumetanide with the 2nd dose of phenobarbital; 3 were withdrawn for reasons unrelated to bumetanide, and 1 because of dehydration. All but 1 infant also received aminoglycosides. Five infants met EEG criteria for seizure reduction (1 on 0.05 mg/kg, 1 on 0.1 mg/kg and 3 on 0.2 mg/kg), and only 2 did not need rescue anti-epileptic drugs (i.e., met rescue criteria; 1 on 0.05 mg/kg and 1 on 0.3 mg/kg). These researchers recorded no short-term dose-limiting toxic effects, but 3 of 11 surviving infants had hearing impairment confirmed on auditory testing between 17 and 108 days of age. The most common non-serious AEs were moderate dehydration in 1, mild hypotension in 7, and mild-to-moderate electrolyte disturbances in 12 infants. The trial was stopped early because of serious AEs and limited evidence for seizure reduction. The authors concluded that these findings suggested that bumetanide as an add-on to phenobarbital did not improve seizure control in newborn infants who have HIE and might increase the risk of hearing loss, highlighting the risks associated with the off-label use of drugs in newborn infants before safety assessment in controlled trials.

Shetty (2015) stated that the risk of seizures is at its highest during the neonatal period, and the most common cause of neonatal seizures is HIE. This enhanced vulnerability is caused by an imbalance in the expression of receptors for excitatory and inhibitory neurotransmission, which is age-dependent. There has been progress in detecting the electrophysiological abnormalities associated with seizures using aEEG. Data from animal studies indicated a variety of risk factors for seizures, but there are limited clinical data looking at the long-term neurodevelopmental consequences of seizures alone. Neonatal seizures are also associated with increased risk of further epileptic seizures; however, it is less clear whether or not this results from an underlying pathology, and whether or not seizures confer additional risk. Phenobarbital and phenytoin are still the first-line anti-epileptic drugs (AEDs) used to treat neonatal seizures, although they are effective in only 1/3 of affected infants. Furthermore, based on findings from animal studies, there are concerns regarding the risks associated with using these AEDs. Clinicians face a difficult challenge because, although seizures can be easily identified using aEEG, treatment options are limited, and there are uncertainties regarding treatment outcomes. The authors concluded that there is a need to obtain long-term follow-up data, comparing groups of infants treated with or without current therapies. If these analyses indicated a definite benefit of treating neonatal seizures, then novel therapeutic approaches should be developed.

Anti-Tissue Plasminogen Activator for the Treatment of Hypoxic Ischemic Encephalopathy

Yang and Kuan (2015) noted that hypoxic-ischemic brain injury is an important cause of neurodevelopmental deficits in neonates. Intra-uterine infection and the ensuing fetal inflammatory responses augment hypoxic-ischemic brain injury and attenuate the effectiveness of therapeutic hypothermia. These investigators reviewed evidences from pre-clinical studies suggesting that the induction of brain parenchymal tissue-type plasminogen activator (tPA) plays an important pathogenic role in these conditions. Moreover, administration of a stable-mutant form of plasminogen activator inhibitor-1 called CPAI confers potent protection against hypoxic-ischemic injury with and without inflammation via different mechanisms. Besides intra-cerebro-ventricular injection, CPAI can also be administered into the brain using a non-invasive intra-nasal delivery strategy, adding to its applicability in clinical use. The authors conclude that the therapeutic potential of CPAI in neonatal care merits further investigation with large-animal models of hypoxia-ischemia and cerebral palsy.

Other Experimental Agents

An UpToDate review on “Clinical features, diagnosis, and treatment of neonatal encephalopathy” (Wu, 2015) states that “A variety of potential neuro-protective treatments are being studied to prevent the cascade of injurious effects after hypoxia-ischemia. As an example, erythropoietin has neuro-protective properties in animal models of hypoxic-ischemic brain injury and neonatal stroke. A preliminary randomized trial of 167 neonates with hypoxic-ischemic encephalopathy found that treatment with recombinant human erythropoietin for 2 weeks, starting within 48 hours of birth, was associated with improved neurologic outcome at 18 months. Confirmation of benefit in larger trials is needed. Additional strategies that may be useful as adjuncts to hypothermia include …. Administration of growth factors (monosialo-gangliosides, brain derived growth factor), nitric oxide synthase inhibitors, and blockers of apoptosis”.


In a phase II, double-blinded, placebo-controlled trial, Wu and colleagues (2016) examined if multiple doses of erythropoietin (Epo) administered with hypothermia improve neuro-radiographical and short-term outcomes of newborns with HIE. These researchers randomized newborns to receive Epo (1,000 U/kg intravenously; n = 24) or placebo (n = 26) at 1, 2, 3, 5, and 7 days of age.  All infants had moderate/severe encephalopathy; perinatal depression (10 minute Apgar less than 5, pH less than 7.00 or base deficit greater than or equal to 15, or resuscitation at 10 minutes); and received hypothermia.  Primary outcome was neurodevelopment at 12 months assessed by the Alberta Infant Motor Scale and Warner Initial Developmental Evaluation.  Two independent observers rated MRI brain injury severity by using an established scoring system.  The mean age at 1st study drug was 16.5 hours (SD, 5.9).  Neonatal deaths did not significantly differ between Epo and placebo groups (8 % versus 19 %, p = 0.42).  Brain MRI at mean 5.1 days (SD, 2.3) showed a lower global brain injury score in Epo-treated infants (median of 2 versus 11, p = 0.01).  Moderate/severe brain injury (4 % versus 44 %, p = 0.002), subcortical (30 % versus 68 %, p = 0.02), and cerebellar injury (0 % versus 20 %, p = 0.05) were less frequent in the Epo than placebo group.  At mean age 12.7 months (SD, 0.9), motor performance in Epo-treated (n = 21) versus placebo-treated (n = 20) infants were as follows: Alberta Infant Motor Scale (53.2 versus 42.8, p = 0.03); Warner Initial Developmental Evaluation (28.6 versus 23.8, p = 0.05).  The authors concluded that high-doses of Epo given with hypothermia for HIE may result in less MRI brain injury and improved 1-year motor function.

The main drawback of this phase II study was its relatively small sample (n = 24 in the Epo group).  After post-hoc exclusion of 2 patients who later met exclusion criteria, the apparent benefit of Epo on 12-month outcomes was no longer statistically significant.  Without a standardized approach to EEG data collection, these researchers were limited in their ability to accurately diagnose clinical and electrographic seizures across all sites.  Similarly, they were unable to compare MR spectroscopy and diffusion tensor imaging measures across centers due to lack of uniform data collection procedures.  These preliminary findings need to be confirmed in a larger study with an adequate sample size to mitigate bias resulting from unavoidable chance confounding, with a longer period of follow-up to allow for the evaluation of long-term impacts, and with standardized neuroimaging and electrophysiological data collection across sites; and plans are underway to perform a large phase III trial to examine if Epo treatment in conjunction with hypothermia improves the long-term neurologic outcome of infants with HIE.

Juul and colleagues (2018) stated that HIE remains an important cause of neonatal death and frequently leads to significant long-term disability in survivors.  Therapeutic hypothermia, while beneficial, still leaves many treated infants with lifelong disabilities.  Adjunctive therapies are needed, and Epo has the potential to provide additional neuroprotection.  These investigators reviewed the current incidence, mechanism of injury, and sequelae of HIE, and described a new phase-III randomized, placebo-controlled trial of Epo neuroprotection in term and near-term infants with moderate-to-severe HIE treated with therapeutic hypothermia.  They presented an overview of HIE, neuroprotective functions of Epo, and the design of a double-blind, placebo-controlled, multi-center trial of high-dose Epo administration, enrolling 500 neonates of greater than or equal to36 weeks of gestation with moderate or severe HIE diagnosed by clinical criteria.  These researchers noted that Epo has robust neuroprotective effects in pre-clinical studies, and results of phase-I/II clinical trials suggested that multiple high doses of Epo may provide neuroprotection against brain injury in term infants.  The High Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) Trial will evaluate whether high-dose Epo reduces the combined outcome of death or neurodevelopmental disability when given in conjunction with hypothermia to newborns with moderate/severe HIE.

Razak and Hussain (2019) stated that RCTs have demonstrated the safety of EPO in neonates with HIE; however, the evidence is unclear.  In a systematic review and meta-analysis, these researchers examined the role of EPO in peri-natal HIE.  Database search included Embase, Medline, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Cochrane Central Register of Controlled Trials (CENTRAL).  RCTs reporting a death, neurodevelopmental outcomes or brain injury were included.  Two authors extracted the data independently from included studies and assessed the level of evidence (LOE).  A total of 6 RCTs (EPO = 5 and darbepoetin α = 1) involving 454 neonates were included.  A trend toward a lower risk of death was identified in infants treated with EPO [EPO with or without hypothermia: 5 RCTs, 368 participants, RR 0.74, 95 % CI: 0.47 to 1.19, LOE-low; EPO without hypothermia: 4 RCTs, 318 participants, RR 0.89, 95 % CI: 0.49 to 1.32, LOE-low].  EPO treatment without hypothermia compared to placebo resulted in a reduced risk of cerebral palsy (2 RCTs, 230 participants, RR 0.47, 95 % CI: 0.27 to 0.80, LOE-moderate) and moderate-to-severe cognitive impairment (2 RCTs, 226 participants, RR 0.49, 95 % CI: 0.28 to 0.85, LOE-moderate).  A reduced risk of brain injury was identified in EPO treated infants (EPO with or without hypothermia, 2 RCTs, 148 participants, RR 0.70, 95 % CI: 0.53 to 0.92, LOE-moderate).  The authors concluded that EPO administration in neonates with perinatal HIE reduced the risk of brain injury, cerebral palsy and cognitive impairment.  Moreover, these researchers stated that the evidence is limited to suggest its role as an adjuvant to hypothermia; and larger powered trials are underway to overcome this limitation.


Azzopardi and associates (2016) examined if the addition of xenon (Xe) gas, a promising novel therapy, after the initiation of hypothermia for birth asphyxia would result in further improvement. Total body hypothermia plus Xe (TOBY-Xe) was a proof-of-concept, randomized, open-label, parallel-group trial done at 4 neonatal ICUs in the UK.  Eligible infants were 36 to 43 weeks of gestational age, had signs of moderate-to- severe encephalopathy and moderately or severely abnormal background activity for at least 30 minutes or seizures as shown by aEEG, and had 1 of the following: Apgar score of 5 or less 10 minutes after birth, continued need for resuscitation 10 minutes after birth, or acidosis within 1 hour of birth.  Participants were allocated in a 1:1 ratio by use of a secure web-based computer-generated randomization sequence within 12 hours of birth to cooling to a rectal temperature of 33.5°C for 72 hours (standard treatment) or to cooling in combination with 30 % inhaled Xe for 24 hours started immediately after randomization.  The primary outcomes were reduction in lactate to N-acetyl aspartate ratio in the thalamus and in preserved fractional anisotropy in the posterior limb of the internal capsule, measured with magnetic resonance spectroscopy (MRS) and MRI, respectively, within 15 days of birth.  The investigator assessing these outcomes was masked to allocation.  Analysis was by intention-to-treat.  The study was done from January 31, 2012 to September 30, 2014.  These researchers enrolled 92 infants, 46 of whom were randomly assigned to cooling only and 46 to Xe plus cooling; 37 infants in the cooling only group and 41 in the cooling plus Xe group underwent magnetic resonance assessments and were included in the analysis of the primary outcomes.  These investigators noted no significant differences in lactate to N-acetyl aspartate ratio in the thalamus (geometric mean ratio 1.09, 95 % CI: 0.90 to 1.32) or fractional anisotropy (mean difference of -0.01, 95 % CI: -0.03 to 0.02) in the posterior limb of the internal capsule between the 2 groups; 9 infants died in the cooling group and 11 in the Xe group; 2 adverse events were reported in the Xe group: subcutaneous fat necrosis and transient desaturation during the MRI.  No serious adverse events were recorded.  The authors concluded that administration of Xe within the delayed time-frame used in this trial was feasible and apparently safe, but is unlikely to enhance the neuro-protective effect of cooling after birth asphyxia.

Ruegger and colleagues (2018) noted that although TH has been shown to be an effective therapy for neonatal HIE, many cooled infants have poor long-term neurodevelopmental outcomes.  In animal models of neonatal encephalopathy, inhaled xenon combined with TH has been shown to offer better neuroprotection than cooling alone.  These investigators determined the effects of xenon as an adjuvant to TH on mortality and neurodevelopmental morbidity, and to ascertain clinically important side effects of xenon plus TH in newborn infants with HIE.  These researchers also examined early predictors of adverse outcomes and potential side effects of xenon.  They used the standard strategy of the Cochrane Neonatal Review Group to search the Cochrane Library (2017, Issue 8), Medline (from 1966), Embase (from 1966), and PubMed (from 1966) for RCTs and quasi-RCTs.  They also searched conference proceedings and the reference lists of cited articles.  These researchers conducted their most recent search in August 2017.  They included all trials allocating term or late pre-term encephalopathic newborns to TH plus xenon or TH alone, irrespective of timing (starting age and duration) and concentrations used for xenon administration.  Two review authors independently assessed results of searches against pre-determined criteria for inclusion, assessed risk of bias, and extracted data.  They performed meta-analyses using RRs, RDs, and number needed to treat for an additional beneficial outcome (NNTB) with 95 % CIs for dichotomous outcomes and MDs for continuous data.  A single RCT enrolling 92 subjects was eligible for this review.  Researchers had not reported long-term neurodevelopmental outcomes, including the primary outcome of this review -- death or long-term major neurodevelopmental disability in infancy (18 months to 3 years of age).  Xenon plus TH was not associated with reduced mortality at latest follow-up, based upon low-quality evidence.  Investigators noted no substantial differences between groups for other secondary outcomes of this review, such as biomarkers of brain damage assessed with MRI and occurrence of seizures during primary hospitalization.  Available data did not show an increased AE rate in the TH plus xenon group compared with the TH alone group.  The authors concluded that current evidence from 1e small RCT was inadequate to show whether TH plus xenon was safe or effective in near-term and term newborns with HIE.  These researchers stated that further trials reporting long-term neurodevelopmental outcomes are needed.

Docosahexaenoic Acid as Adjunctive Therapy

Huun and colleagues (2018) stated that TH has become the standard of care for newborns with HIE in high and middle income countries.  Docosahexaenoic acid (DHA) has neuroprotective properties of reducing excitotoxicity, neuro-inflammation and apoptosis in rodent models.  These researchers examined if post-hypoxic intravenous (i.v.) administration of DHA will reduce 1H+magnetic resonance spectroscopy (MRS) biomarkers and gene expression of inflammation and apoptosis both with and without hypothermia in a large animal model.  A total of 55 piglets were randomized to severe global hypoxia (n = 48) or not (sham, n = 7).  Hypoxic piglets were further randomized by factorial design: Vehicle (VEH), DHA, VEH + hypothermia (HT), or DHA + HT; 5 mg/kg DHA (i.v.) was given 210 mins after end of hypoxia; 2-way ANOVA analyses were performed with DHA and hypothermia as main effects.  Cortical lactate/N-acetylaspartate (Lac/NAA) was significantly reduced in DHA + HT compared to HT; DHA had significant main effects on increasing NAA and glutathione in the hippocampus; TH significantly reduced the Lac/NAA ratio and protein expression of IL-1β and TNFα in the hippocampus and reduced troponin T in serum.  Neuropathology showed significant differences between sham and hypoxia, but no differences between intervention groups.  The authors concluded that DHA and TH significantly improved specific 1H+MRS biomarkers in this short-term follow-up model of hypoxia-ischemia. These investigators stated that longer recovery periods are needed to examine if DHA can offer translational neuroprotection.

Inhaled Carbon Monoxide (CO) Therapy

In a pilot study, Douglas-Escobar and colleagues (2018) evaluated the efficacy and safety (i.e., carboxyhemoglobin concentration of carbon monoxide (CO)) as a putative neuroprotective therapy in neonates.  Neonatal C57BL/6 mice were exposed to CO at a concentration of either 200 or 250 ppm for a period of 1 hour.  The pups were then sacrificed at 0, 10, 20, 60, 120, 180, and 240 mins after exposure to either concentration of CO, and blood was collected for analysis of carboxyhemoglobin.  Following the safety study, 7-day old pups underwent a unilateral carotid ligation.  After recovery, the pups were exposed to a humidified gas mixture of 8 % oxygen and 92 % nitrogen for 20 mins in a hypoxia chamber.  One hour after the hypoxia exposure, the pups were randomized to 1 of 2 groups: air (HI+A) or carbon monoxide (HI+CO).  An inhaled dose of 250 ppm of CO was administered to the pups for 1 hour per day for a period of 3 days.  At 7 days post-injury, the pups were sacrificed and the brains analyzed for cortical and hippocampal volumes.  CO exposure at 200 and 250 ppm produced a peak carboxyhemoglobin concentration of 21.52 ± 1.18 % and 27.55 ± 3.58 %, respectively.  The carboxyhemoglobin concentrations decreased rapidly, reaching control concentrations by 60 mins post exposure.  At 14 days of age (7 days post-injury), the HI+CO (treated with 1 hour per day of 250 ppm of CO for 3 days post-injury) had significant preservation of the ratio of ipsilateral to contralateral cortex (median of 1.07, 25 % 0.97, 75 % 1.23, n = 10) compared the HI+A group (p < 0.05).  The authors concluded that CO exposure of 250 ppm did not reach carboxyhemoglobin concentrations that would induce acute neurologic abnormalities and was effective in preserving cortical volumes following hypoxic-ischemic injury.  These investigators stated that future experiments will focus on the functional outcomes of pups exposed to CO following HI, examining possible synergy with hypothermia and using transgenic mice to dissect the mechanism of action of CO in modulating injury post-HI through the ARE-Nrf2-Keap1 pathway.  If future experiments are promising, large animal models will need to be utilized before proceeding with human trials, as rodents do not have hemoglobin F (only embryonic hemoglobin that switches to adult hemoglobin at E17).  Thus, the pharmacokinetic of CO in neonates should be tested in large mammals to adjust for fetal hemoglobin prior to human application.

The authors noted that a drawback of this study was the inability to sample carboxyhemoglobin from the same pup over time.  The size of the pups precluded multiple samplings and the pups were sacrificed at each time-point that the carboxyhemoglobin concentration was measured to obtain adequate blood volume for analysis.  In addition, the cardiorespiratory status was also not monitored during the administration of CO and the neurologic outcomes were preliminary.  They stated that future studies will address any physiologic disturbances during the administration of CO and perform intricate neurologic testing to understand the short- and long-term outcomes following CO exposure.

Monosialoganglioside as Adjunctive Therapy

Sheng and Li (2017) noted that ganglioside has a neuroprotective role in neonatal HIE.  In a meta-analysis, these researchers evaluated the neurological outcomes of monosialoganglioside as adjuvant treatment for neonatal HIE.  A comprehensive literature search was made in the PubMed, Embase, Cochrane Library, Wanfang, CNKI, VIP databases through October 2016; RCTs comparing monosialoganglioside with the usual treatment for newborns having HIE deemed eligible.  Weighted mean difference (WMD) and RR with 95 % CI were calculated for continuous and dichotomous data, respectively.  A total of 10 trials consisting of 787 neonates were included.  Adjuvant treatment with monosialoganglioside significantly reduced major neurodevelopmental disabilities (RR = 0.35; 95 % CI: 0.21 to 0.57), cerebral palsy (RR = 0.32; 95 % CI: 0.12 to 0.87), mental retardation (RR = 0.31; 95 % CI: 0.11 to 0.88) as well as improved the mental (WMD = 14.95; 95 % CI: 7.44 to 22.46) and psycho-motive (WMD = 13.40; 95 % CI: 6.69 to 20.11) development index during the follow-up.  Furthermore, monosialoganglioside significantly improved Neonatal Behavioral Neurological Assessment (NBNA) scores (WMD = 2.91; 95 % CI: 2.05 to 3.78) compared with the usual treatment.  However, adverse effects associated with monosialoganglioside were poorly reported in the included trials.  The authors concluded that adjuvant treatment with monosialoganglioside had beneficial effects in improving neurological outcomes in neonatal HIE.  However, these findings should be interpreted with caution because of methodological flaws in the included trials.  Furthermore, safety of monosialoganglioside use should also be further evaluated.  These investigators stated that determination of the optimal duration of intervention and long-time follow-up should be considered in future trials; future studies should also explore the underlying mechanisms of the protective roles of monosialoganglioside.

The authors stated that this study had several drawbacks.  First, most included trials lacked sufficient information on the randomization or allocation concealment method, therefore, the methodological flaws of the included trials were an important concern.  Second, potential publication bias could not be excluded because all included trials were published in Chinese.  Finally, statistical heterogeneity was present in pooling continuous data.  The differences in duration of regimens, follow-up periods, and severity of HIE across the included trials may partly contribute to the observed heterogeneity.

Nair and Kumar (2018) stated that HIE presents a significant clinical burden with its high mortality and morbidity rates globally; TH is now standard of care for infants with moderate-to-severe HIE, but has not definitively changed outcomes in severe HIE.  These investigators discussed newer promising markers that may help the clinician identify severity of HIE; they also discussed therapies that are beneficial and agents that hold promise for neuroprotection, both for use either alone or as adjuncts to TH.  These include endogenous pathway modifiers such as Epo and analogs, melatonin, and remote ischemic post-conditioning.  Stem cells have therapeutic potential in this condition, as in many other neonatal conditions.  Of the agents listed, only Epo and analogs are currently being evaluated in large RCTs.  Exogenous therapies such as argon and xenon, allopurinol, monosialogangliosides, and magnesium sulfate continue to be investigated.  These alternative modalities may be especially important in mild HIE and in areas of the world where there is limited access to expensive hypothermia equipment and services.

Photobiomodulation Therapy

Tucker and colleagues (2018) noted that photobiomodulation (PBM) has been demonstrated as a neuroprotective strategy, but its effect on perinatal HIE is still unknown.  The current study was designed to shed light on the potential beneficial effect of PBM on neonatal brain injury induced by hypoxia ischemia (HI) in a rat model.  Post-natal rats were subjected to hypoxic-ischemic insult, followed by a 7-day PBM treatment via a continuous wave diode laser with a wavelength of 808 nm.  These researchers demonstrated that PBM treatment significantly reduced HI-induced brain lesion in both the cortex and hippocampal CA1 sub-regions.  Molecular studies indicated that PBM treatment profoundly restored mitochondrial dynamics by suppressing HI-induced mitochondrial fragmentation.  Further investigation of mitochondrial function revealed that PBM treatment remarkably attenuated mitochondrial membrane collapse, accompanied with enhanced ATP synthesis in neonatal HI rats.  In addition, PBM treatment led to robust inhibition of oxidative damage, manifested by significant reduction in the productions of 4-HNE, P-H2AX (S139), malondialdehyde (MDA), as well as protein carbonyls.  Finally, PBM treatment suppressed the activation of mitochondria-dependent neuronal apoptosis in HI rats, as evidenced by decreased pro-apoptotic cascade 3/9 and TUNEL-positive neurons.  The authors concluded that these findings demonstrated that PBM treatment contributed to a robust neuroprotection via the attenuation of mitochondrial dysfunction, oxidative stress, and final neuronal apoptosis in the neonatal HI brain.  These preliminary findings need to be further investigated.

Soluble Form of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (sLOX-1) as a Novel Biomarker for Neonatal Hypoxic-Ischemic Encephalopathy

In a pilot study, Akamatsu and colleagues (2019) examined the soluble form of lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) as a biomarker of severity staging and prognosis in neonatal HIE.  These researchers performed an observational study enrolling 27 infants with HIE and 45 control infants of gestational age greater than or equal to 36 weeks and birth-weight greater than or equal to 1,800 g.  The HIE criteria were pH less than or equal to 7.0 or a base deficit of greater than or equal to 16 mmol/L within 60 mins after birth, and a 10-min Apgar score of less than or equal to 5 or resuscitation time of greater than or equal to 10 mins.  HIE severity was evaluated using modified Sarnat staging.  These investigators measured plasma sLOX-1 level and assessed general and neurologic signs at discharge, and classified infants with no neurosensory impairments as intact survival.  sLOX-1 level within 6 hours after birth was correlated with the severity of HIE.  sLOX-1 differentiated moderate-severe HIE (median, 1,017 pg/ml; IQR, 553 to 1,890 pg/ml) from mild HIE (median of 339 pg/ml; inter-quartile range [IQR], 288 to 595 pg/ml; p = 0.007).  The sensitivity and specificity of the differentiation with a cut-off value of greater than or equal to 550 pg/ml were 80.0 % and 83.3 %, respectively.  In 19 infants with TH, a sLOX-1 cutoff value of less than 1,000 pg/ml differentiated intact survival (median of 761 pg/ml; IQR, 533 to 1,610 pg/ml) from death or neurosensory impairment (median, of 1,947 pg/ml; IQR, 1,325 to 2,506 pg/ml; p = 0.019) with 100 % specificity and a positive predictive value (PPV).  The authors concluded that sLOX-1 may be a useful biomarker of neonatal HIE for severity staging and outcome prediction.  Moreover, these researchers stated that further investigations will facilitate its clinical use.

N-Acetylaspartate as a Biomarker of Outcome Prediction for Hypoxic Ischemic Encephalopathy

Zou and colleagues (2018) noted that HIE is a major contributor to child mortality and morbidity; and reliable prognostication for HIE is important.  Proton MRS (1H-MRS) is a quantitative, non-invasive method that has been demonstrated to be a suitable complementary tool for prediction.  These investigators examined the prognostic capability of 1H-MRS in the era of TH.  Databases, namely Medline, Embase, Web of Science, and the Cochrane library (Cochrane Center Register of Controlled Trials), were searched for studies published before July 17, 2017.  Study selection and data extraction were performed by 2 independent reviewers.  The mean difference (MD) or standardized MD (SMD) and 95 % CI were calculated using random-effects models.  Subgroup analyses were conducted based on the use of TH.  Among the 1,150 relevant studies, 7 were included for meta-analysis, but only 2 small studies were conducted under TH.  For 1H-MRS measurement, 3 peak area ratios revealed predictive values for adverse outcomes in TH subgroup and the combined results (with and without TH): N-acetylaspartate (NAA) / creatine in basal ganglia / thalamus (BG/T) in TH (MD -0.31, 95 % CI: -0.55 to -0.07) and combined results (MD -0.37, 95 % CI: -0.49 to -0.25); NAA / choline in BG/T in TH (MD -0.89, 95 % CI: 1.43 to -0.35) and combined results (MD -0.25, 95 % CI: -0.42 to -0.07); and myo-inositol / choline in cerebral cortex in TH (MD -1.94, 95 % CI: -3.69 to -0.19) and combined results (MD -1.64, 95 % CI: -2.64 to -0.64).  Moreover, NAA relative concentration was associated with adverse outcomes: in TH (MD -0.04, 95 % CI: -0.06 to -0.02) and combined results (MD -0.06, 95 % CI: -0.11 to -0.01) in white matter; in TH (MD -0.04, 95 % CI: -0.07 to -0.01) and combined results (MD -0.05, 95 % CI: -0.07 to -0.02) in gray matter.  The authors concluded that NAA may be a potential marker in outcome prediction for all HIE subjects.  It appeared that MDs for the ratios including NAA were larger than for its relative concentration, and thus were more likely to be measurable in a clinical context.  These researchers stated that larger, prospective, multicenter studies with a standardized protocol for both measurement protocols and analysis methods are needed in future studies.

Table: CPT Codes / HCPCS Codes / ICD-10 Codes
Code Code Description

Information in the [brackets] below has been added for clarification purposes.   Codes requiring a 7th character are represented by "+":

CPT codes covered if selection criteria are met:

99184 Initiation of selective head or total body hypothermia in the critically ill neonate, includes appropriate patient selection by review of clinical, imaging and laboratory data, confirmation of esophageal temperature probe location, evaluation of amplitude EEG, supervision of controlled hypothermia, and assessment of patient tolerance of cooling

CPT codes not covered for indications listed in the CPB :

Serum interleukin-6, Activin A, Glial fibrillary acidic protein (GFAP), MicroRNA (miRNA), S100 calcium-binding protein B (S-100β), Tau protein, Docosahexaenoic acid therapy, Inhaled carbon monoxide (CO) therapy, ), Monosialoganglioside or Photobiomodulation therapy, phosphorylated axonal neurofilament heavy chain (pNF-H), N-acetylaspartate, Soluble form of lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) - no specific code
38204 - 38205, 38207 - 38215, 38230, 38240, 38242 Bone marrow or stem cell services/procedures-allogenic
38241 Hematopoietic progenitor cell (HPC); autologous transplantation
82550 Creatine kinase (CK), (CPK); total
82552 Creatine kinase (CK), (CPK); isoenzymes
86316 Immunoassay for tumor antigen, other antigen, quantitative (eg, CA 50, 72-4, 549), each [neuron-specific enolase (NSE)]
97810 - 97814 Acupuncture
99481 Total body systemic hypothermia in a critically ill neonate per day (List separately in addition to code for primary procedure)
99482 Selective head hypothermia in a critically ill neonate per day (List separately in addition to code for primary procedure)

HCPCS codes not covered for indications listed in the CPB:

Allopurinol - No specific code:

J0153 Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds)
J0881 Injection, darbepoetin alfa, 1 microgram (non-ESRD use)
J0882 Injection, darbepoetin alfa, 1 microgram (for ESRD use)
J0885 Injection, epoetin alfa, (for non-ESRD use), 1000 units
J0887 - J0888 Injection, epoetin beta, 1 microgram
J3230 Injection, chlorpromazine HCI, up to 50 mg
J3475 Injection, magnesium sulfate, per 500 mg
J7502 Cyclosporine, oral, 100 mg
J7515 Cyclosporine, oral, 25 mg
J7516 Cyclosporine, parenteral, 250 mg
J7604 Acetylcysteine, inhalation solution, compounded product, administered through DME, unit dose form, per gram
Q4081 Injection, epoetin alfa, 100 units (for ESRD on dialysis)

ICD-10 codes covered if selection criteria are met:

P91.62 Moderate hypoxic ischemic encephalopathy [HIE]
P91.63 Severe hypoxic ischemic encephalopathy [HIE]

The above policy is based on the following references:

  1. Gluckman PD, Wyatt JS, Azzopardi D, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: Multicentre randomised trial. Lancet. 2005;365(9460):663-670.
  2. Shankaran S, Laptook AR, Ehrenkranz RA, et al; National Institute of Child Health and Human Development Neonatal Research Network. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med. 2005;353(15):1574-1584.
  3. Perlman JM. Intervention strategies for neonatal hypoxic-ischemic cerebral injury. Clin Ther. 2006;28(9):1353-1365.
  4. Schulzke SM, Rao S, Patole SK. A systematic review of cooling for neuroprotection in neonates with hypoxic ischemic encephalopathy - are we there yet? BMC Pediatr. 2007;7:30.
  5. Jacobs S, Hunt R, Tarnow-Mordi W, et al. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst Rev. 2007;(4):CD003311.
  6. Azzopardi DV, Strohm B, Edwards AD, et al; TOBY Study Group. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med. 2009;361(14):1349-1358.
  7. Sarkar S, Barks JD, Bhagat I, Donn SM. Effects of therapeutic hypothermia on multiorgan dysfunction in asphyxiated newborns: Whole-body cooling versus selective head cooling. J Perinatol. 2009;29(8):558-563.
  8. Zhu C, Kang W, Xu F, et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics. 2009;124(2):e218-e226.
  9. Pfister RH, Soll RF. Hypothermia for the treatment of infants with hypoxic-ischemic encephalopathy. J Perinatol. 2010;30 Suppl:S82-S87.
  10. Selway LD. State of the science: Hypoxic ischemic encephalopathy and hypothermic intervention for neonates. Adv Neonatal Care. 2010;10(2):60-66.
  11. Rutherford M, Ramenghi LA, Edwards AD, et al. Assessment of brain tissue injury after moderate hypothermia in neonates with hypoxic-ischaemic encephalopathy: A nested substudy of a randomised controlled trial. Lancet Neurol. 2010;9(1):39-45.
  12. Lando A, Jonsbo F, Hansen BM, Greisen G. Induced hypothermia in infants born with hypoxic-ischaemic encephalopathy. Ugeskr Laeger. 2010;172(19):1433-1437.
  13. Simbruner G, Mittal RA, Rohlmann F, et al. Systemic hypothermia after neonatal encephalopathy: Outcomes of neo.nEURO.network RCT. Pediatrics. 2010;126(4):e771-e778.
  14. Zhou WH, Cheng GQ, Shao XM, et al; China Study Group. Selective head cooling with mild systemic hypothermia after neonatal hypoxic-ischemic encephalopathy: A multicenter randomized controlled trial in China. J Pediatr. 2010;157(3):367-372.
  15. Edwards AD, Brocklehurst P, Gunn AJ, et al. Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: Synthesis and meta-analysis of trial data. BMJ. 2010;340:c363.
  16. Shah PS. Hypothermia: A systematic review and meta-analysis of clinical trials. Semin Fetal Neonatal Med. 2010;15(5):238-246.
  17. Cilio MR, Ferriero DM. Synergistic neuroprotective therapies with hypothermia. Semin Fetal Neonatal Med. 2010;15(5):293-298.
  18. Wintermark P, Boyd T, Gregas MC, et al. Placental pathology in asphyxiated newborns meeting the criteria for therapeutic hypothermia. Am J Obstet Gynecol. 2010;203(6):579.e1-e9.
  19. Rizzotti A, Bas J, Cuestas E. Efficacy and security of therapeutic hypothermia for hypoxic ischemic encephalopathy: A meta-analysis. Rev Fac Cien Med Univ Nac Cordoba. 2010;67(1):15-23.
  20. Jacobs SE, Morley CJ, Inder TE, et al; Infant Cooling Evaluation Collaboration. Whole-body hypothermia for term and near-term newborns with hypoxic-ischemic encephalopathy: A randomized controlled trial. Arch Pediatr Adolesc Med. 2011;165(8):692-700.
  21. Blanco D, García-Alix A, Valverde E, et al; Comisión de Estándares de la Sociedad Española de Neonatología (SEN). Neuroprotection with hypothermia in the newborn with hypoxic-ischaemic encephalopathy. Standard guidelines for its clinical application. An Pediatr (Barc). 2011;75(5):341.e1-e20.
  22. Shankaran S, Pappas A, McDonald SA, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Predictive value of an early amplitude integrated electroencephalogram and neurologic examination. Pediatrics. 2011;128(1):e112-e120.
  23. Shankaran S, Pappas A, McDonald SA, et al; Eunice Kennedy Shriver NICHD Neonatal Research Network. Childhood outcomes after hypothermia for neonatal encephalopathy. N Engl J Med. 2012;366(22):2085-2092.
  24. Chaudhari T, McGuire W. Allopurinol for preventing mortality and morbidity in newborn infants with hypoxic-ischaemic encephalopathy. Cochrane Database Syst Rev. 2012;7:CD006817.
  25. Olsen SL, Dejonge M, Kline A, et al. Optimizing therapeutic hypothermia for neonatal encephalopathy. Pediatrics. 2013;131(2):e591-e603.
  26. Jacobs SE, Berg M, Hunt R, et al. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst Rev. 2013;1:CD003311.
  27. Wong V, Cheuk DK, Chu V. Acupuncture for hypoxic ischemic encephalopathy in neonates. Cochrane Database Syst Rev. 2013;1:CD007968.
  28. Galvao TF, Silva MT, Marques MC, et al. Hypothermia for perinatal brain hypoxia-ischemia in different resource settings: A systematic review. J Trop Pediatr. 2013;59(6):453-459.
  29. Tagin M, Shah PS, Lee KS. Magnesium for newborns with hypoxic-ischemic encephalopathy: A systematic review and meta-analysis. J Perinatol. 2013;33(9):663-669.
  30. Cotten CM, Murtha AP, Goldberg RN, et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. J Pediatr. 2014;164(5):973-979.
  31. Gonzales-Portillo GS, Reyes S, Aguirre D, et al. Stem cell therapy for neonatal hypoxic-ischemic encephalopathy. Front Neurol. 2014;5:147.
  32. Dingley J, Tooley J, Liu X, et al. Xenon ventilation during therapeutic hypothermia in neonatal encephalopathy: A feasibility study. Pediatrics. 2014;133(5):809-818.
  33. Galinsky R, Bennet L, Groenendaal F, et al. Magnesium is not consistently neuroprotective for perinatal hypoxia-ischemia in term-equivalent models in preclinical studies: A systematic review. Dev Neurosci. 2014;36(2):73-82.
  34. McNellis E, Fisher T, Kilbride HW. Safety and effectiveness of whole body cooling therapy for neonatal encephalopathy on transport. Air Med J. 2015;34(4):199-206.
  35. Yang C, Hao Z, Zhang LL, Guo Q. Efficacy and safety of acupuncture in children: An overview of systematic reviews. Pediatr Res. 2015;78(2):112-119.
  36. Atici A, Celik Y, Gulasi S, et al. Comparison of selective head cooling therapy and whole body cooling therapy in newborns with hypoxic ischemic encephalopathy: Short term results. Turk Pediatri Ars. 2015;50(1):27-36.
  37. Wu YW, Gonzalez FF. Erythropoietin: A novel therapy for hypoxic-ischaemic encephalopathy? Dev Med Child Neurol. 2015;57 Suppl 3:34-39.
  38. Pressler RM, Boylan GB, Marlow 3, et al; NEonatal seizure treatment with Medication Off-patent (NEMO) consortium. Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): An open-label, dose finding, and feasibility phase 1/2 trial. Lancet Neurol. 2015;14(5):469-477.
  39. Shetty J. Neonatal seizures in hypoxic-ischaemic encephalopathy -- risks and benefits of anticonvulsant therapy. Dev Med Child Neurol. 2015;57 Suppl 3:40-43.
  40. Yang D, Kuan CY. Anti-tissue plasminogen activator (tPA) as an effective therapy of neonatal hypoxia-ischemia with and without inflammation. CNS Neurosci Ther. 2015;21(4):367-373.
  41. Wu Y. Clinical features, diagnosis, and treatment of neonatal encephalopathy. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed July 2015.
  42. Celik Y, Atıcı A, Gülası S, et al. The effects of selective head cooling versus whole-body cooling on some neural and inflammatory biomarkers: A randomized controlled pilot study. Ital J Pediatr. 2015;41:79.
  43. Davidson JO, Wassink G, van den Heuij LG, et al. Therapeutic hypothermia for neonatal hypoxic-ischemic encephalopathy - where to from here? Front Neurol. 2015;6:198.
  44. Azzopardi D, Robertson NJ, Bainbridge A, et al. Moderate hypothermia within 6 h of birth plus inhaled xenon versus moderate hypothermia alone after birth asphyxia (TOBY-Xe): A proof-of-concept, open-label, randomised controlled trial. Lancet Neurol. 2016;15(2):145-153.
  45. Wu YW, Mathur AM, Chang T, et al. High-dose erythropoietin and hypothermia for hypoxic-ischemic encephalopathy: A phase II trial. Pediatrics. 2016;137(6).
  46. Celik Y, Atıcı A, Gulası S, et al. Comparison of selective head cooling versus whole-body cooling. Pediatr Int. 2016;58(1):27-33.
  47. Lv H, Wang Q, Wu S, et al. Neonatal hypoxic ischemic encephalopathy-related biomarkers in serum and cerebrospinal fluid. Clin Chim Acta. 2015;450:282-297.
  48. Zaigham M, Lundberg F, Hayes R, et al.  Umbilical cord blood concentrations of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) in neonates developing hypoxic-ischemic encephalopathy. J Matern Fetal Neonatal Med. 2016;29(11):1822-1828.
  49. Weinhouse GL, Young GB. Hypoxic-ischemic brain injury: Evaluation and prognosis. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed July 2017.
  50. Wu Y. Clinical features, diagnosis, and treatment of neonatal encephalopathy.UpToDate [online serial]. Waltham, MA: UpToDate; reviewed July 2017.
  51. Martinello K, Hart AR, Yap S, et al. Management and investigation of neonatal encephalopathy: 2017 update. Arch Dis Child Fetal Neonatal Ed. 2017;102(4):F346-F358.
  52. Sheng L, Li Z. Adjuvant treatment with monosialoganglioside may improve neurological outcomes in neonatal hypoxic-ischemic encephalopathy: A meta-analysis of randomized controlled trials. PLoS One. 2017;12(8):e0183490.
  53. Douglas-Escobar M, Mendes M, Rossignol C, et al. A pilot study of inhaled CO therapy in neonatal hypoxia-ischemia: Carboxyhemoglobin concentrations and brain volumes. Front Pediatr. 2018;6:120
  54. Nair J, Kumar VHS. Current and emerging therapies in the management of hypoxic ischemic encephalopathy in neonates. Children (Basel). 2018;5(7).
  55. Favie LMA, Cox AR, van den Hoogen A, et al. Nitric oxide synthase inhibition as a neuroprotective strategy following hypoxic-ischemic encephalopathy: Evidence from animal studies. Front Neurol. 2018;9:258.
  56. Juul SE, Comstock BA, Heagerty PJ, et al. High-dose erythropoietin for asphyxia and encephalopathy (HEAL): A randomized controlled trial - background, aims, and study protocol. Neonatology. 2018;113(4):331-338.
  57. Huun MU, Garberg H, Loberg EM, et al. DHA and therapeutic hypothermia in a short-term follow-up piglet model of hypoxia-ischemia: Effects on H+MRS biomarkers. PLoS One. 2018;13(8):e0201895.
  58. Patil UP, Mally PV, Wachtel EV. Serum biomarkers of neuronal injury in newborns evaluated for selective head cooling: A comparative pilot study. J Perinat Med. 2018;46(8):942-947.
  59. Tucker LD, Lu Y, Dong Y, et al. Photobiomodulation therapy attenuates hypoxic-ischemic injury in a neonatal rat model. J Mol Neurosci. 2018;65(4):514-526.
  60. Ruegger CM, Davis PG, Cheong JL. Xenon as an adjuvant to therapeutic hypothermia in near-term and term newborns with hypoxic-ischaemic encephalopathy. Cochrane Database Syst Rev. 2018;8:CD012753.
  61. Zou R, Xiong T, Zhang L, et al. Proton magnetic resonance spectroscopy biomarkers in neonates with hypoxic-ischemic encephalopathy: A systematic review and meta-analysis. Front Neurol. 2018;9:732.
  62. Razak A, Hussain A. Erythropoietin in perinatal hypoxic-ischemic encephalopathy: A systematic review and meta-analysis. J Perinat Med. 2019;47(4):478-489.
  63. Akamatsu T, Sugiyama T, Aoki Y, et al. A pilot study of soluble form of LOX-1 as a novel biomarker for neonatal hypoxic-ischemic encephalopathy. J Pediatr. 2019;206:49-55.